Dr Charles Bidgood

Find Charles Bidgood on

EMCR Delegate (TRI)

Biography

Dr Charlie Bidgood is an early career postdoctoral researcher at the Australian Prostate Cancer Research Centre – Queensland (APCRC-Q) with an extensive research background in cancer biology and cellular metabolism. Throughout his recently completed doctoral studies, his research focused on developing innovative therapeutic strategies for men with advanced prostate cancer using a range of novel metabolic approaches. As a result of his training, Charlie gained extensive experience in high-content quantitative singe-cell microscopy, the development of novel automated imaging-analysis pipelines, application of metabolomic analyses, and numerous biochemical and computational techniques. The outcomes of his research involved shedding new light on acquired drug resistance induced by advanced prostate cancer therapies by exploring the complex metabolic processes implicated within the response. Charlie has presented his work at the EACR Cancer Metabolism Meeting (Bilbao, Spain), the University of Bern Institute of Tissue Medicine and Pathology (Bern, Switzerland) as well as the KU Leuven Centre for Cancer Biology (Leuven, Belgium) to academic leaders of the cancer metabolism field. Most recently, he also presented his work on mitochondrial energy remodelling in cancer at the Australian Cancer and Metabolism Meeting (Melbourne, Australia) for which he was awarded best short talk. Charlie has also undertaken the role of as sponsorship manager of the Queensland branch of the Australian Society of Medical Research (ASMR), which promotes scientific, political, and public advocacy for the Australian health and medical research sector. In this role he is responsible for liaising with industry, pharmaceutical and academic institutions to secure funding for the annual Queensland ASMR Medical Research Week.

Qualifications

  • Doctor of Philosophy 2023
  • Bachelor of Biomedical Science (Honours) 2018
  • Bachelor of Biomedical Science (Human Physiology) 2017

Research Outputs

  1. Young, R. S. E., Bowman, A. P., Williams, E. D., Tousignant, K. D., Bidgood, C. L., Narreddula, V. R., Gupta, R., Marshall, D. L., Poad, B. L. J., Nelson, C. C., Ellis, S. R., Heeren, R. M. A., Sadowski, M. C., & Blanksby, S. J. (2021). Apocryphal FADS2 activity promotes fatty acid diversification in cancer. Cell Reports, 34(6), 108738. https://doi.org/10.1016/j.celrep.2021.108738
  2. Kumar, R., Bidgood, C. L., Levrier, C., Gunter, J. H., Nelson, C. C., Sadowski, M. C., & Davis, R. A. (2020). Synthesis of a Unique Psammaplysin F Library and Functional Evaluation in Prostate Cancer Cells by Multiparametric Quantitative Single Cell Imaging. Journal of Natural Products, 83(8), 2357–2366. https://doi.org/10.1021/acs.jnatprod.0c00121
  3. Philp, L. K., Rockstroh, A., Sadowski, M. C., Taherian Fard, A., Lehman, M., Tevz, G., Libério, M. S., Bidgood, C. L., Gunter, J. H., McPherson, S., Bartonicek, N., Wade, J. D., Otvos Jr, L., & Nelson, C. C. (2021). Leptin antagonism inhibits prostate cancer xenograft growth and progression. Endocrine-Related Cancer. https://doi.org/10.1530/erc-20-0405